Combination Therapy for Ewing's Sarcoma
Author Information
Author(s): Karmakar Surajit, Choudhury Subhasree Roy, Banik Naren L., Ray Swapan K.
Primary Institution: University of South Carolina School of Medicine
Hypothesis
The combination of N-(4-hydroxyphenyl) retinamide (4-HPR) and genistein (GST) will be more effective in controlling the growth of Ewing's sarcoma than either treatment alone.
Conclusion
The combination of 4-HPR and GST is highly effective in inhibiting Ewing's sarcomas in vivo.
Supporting Evidence
- Combination therapy significantly reduced tumor volume compared to control and monotherapy groups.
- 4-HPR alone inhibited tumor cell proliferation, while GST alone induced some cell death.
- Combination therapy increased the Bax : Bcl-2 ratio, promoting apoptosis.
- Downregulation of survival factors like NF-κB and angiogenic factors like VEGF and FGF2 was observed.
- Activation of caspase-3 was significantly increased in the combination therapy group.
Takeaway
Researchers found that using two drugs together can help fight a type of cancer called Ewing's sarcoma better than using just one drug.
Methodology
The efficacy of combination therapy was evaluated using histopathological parameters and molecular mechanisms were detected using Western blotting and immunofluorescence microscopy.
Participant Demographics
Female athymic nu/nu mice were used for the xenograft studies.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website